Lente insulin (porcine lente, Vetsulin) at 0.25 U/kg SC q12h is the recommended first-line starting dose for diabetic dogs, rounded to the nearest whole unit, with most dogs achieving control at an average of 0.5 U/kg q12h and a range of 0.2–1.0 U/kg q12h.AAHA Clinical G…
Insulin glargine 300 U/mL (IGla300) administered q24h is an emerging alternative with a favorable safety profile. Glycemic control is achieved with q24h IGla300 in 72% of dogs without concurrent disease and 50% of dogs with concurrent disease.Journal of Vete… The starting dose is 0.5 U/kg q24h, with rapid titration facilitated by continuous glucose monitoring.Journal of Vete… The clinical hypoglycemia rate with IGla300 is 5% in dogs without concurrent disease — substantially lower than porcine lente (38.6%), insulin detemir (40%), and insulin glargine 100 U/mL (20%).Journal of Vete…
Insulin degludec 100 U/mL (IDeg100) is a further basal option with a clinical hypoglycemia rate of 3%, comparable to IGla300 at 6%. The median starting dose is 0.6 U/kg, escalated to a median final dose of 1.3 U/kg over a median of 14 days.Journal of Vete… Median time to glycemic control with IDeg100 is shorter than IGla300 (17 days), porcine lente (35 days), IGla100 (38 days), and protamine zinc insulin (42 days).Journal of Vete…
Insulin detemir is a long-acting option for dogs but requires particular caution due to high potency. The starting dose is 0.1 U/kg, and small dogs are at higher risk for hypoglycemic excursions.AAHA Clinical G… Dosage increases should not occur more frequently than every 1–2 weeks regardless of insulin type.AAHA Clinical G…
Dose adjustment intervals and glucose curve interpretation should drive titration cadence. Insulin doses should not be increased more often than every 1–2 weeks, and a dosing window of ±2 hours on each side of the scheduled interval is acceptable.AAHA Clinical G… Continuous or flash glucose monitoring accelerates safe dose escalation for basal insulins such as IGla300 and IDeg100 by providing real-time data that traditional curves cannot.Journal of Vete…+1
| Insulin | Starting Dose | Route/Frequency | Glycemic Control Rate | Hypoglycemia Rate |
|---|---|---|---|---|
| Porcine lente (Vetsulin) | 0.25 U/kg | SC q12h | Not reported | 38.6% |
| IGla300 | 0.5 U/kg | SC q24h | 72% (no concurrent disease); 50% (with concurrent disease) | 5% (no concurrent disease) |
| IDeg100 | 0.6 U/kg (median start) → 1.3 U/kg (median final) | SC q24h | Not reported as % | 3% |
| Detemir | 0.1 U/kg | SC q12h | Not reported | 40% |
Would you like guidance on how to structure the dose escalation protocol for IGla300 or IDeg100 using continuous glucose monitoring?